The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The ERBB network facilitates KRAS-driven lung tumorigenesis
Open accessPublished version of a preprint
Abstract
Abstract KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling, however recent data suggest that this independence may not be absolute. Here we show that initiation and progression of KRAS-driven lung tumors requires input from ERBB family RTKs: Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS driven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRas G12D -driven lung tumors. We present evidence that ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS mutant tumor cells in culture and progression to invasive disease in vivo . Importantly, brief pharmacological inhibition of the ERBB network significantly enhances the therapeutic benefit of MEK inhibition in an autochthonous tumor setting. Our data suggest that lung cancer patients with KRAS-driven disease may benefit from inclusion of multi-ERBB inhibitors in rationally designed treatment strategies. One Sentence Summary G12 Mutant KRAS requires tonic ERBB network activity for initiation and maintenance of lung cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, pan-ERBB inhibition enhanced the potency of MEK inhibition in vitro and in vivo.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [61]
In the citing paper
“ERBB activity establishes a feed-forward loop to amplify signaling through the core RAS-ERK cascade to sustain survival and proliferation in KRAS-mutant NSCLC.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [61]
In the citing paper
“multiple ERBB ligands (e.g., Areg, Ereg, Nrg3, Nrg4, and Hbegf) and receptors (for example, Erbb2 and Erbb3) were highly expressed in a KRASG12D mouse model.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Allemani, C., Weir, H. K., Carreira, H., Harewood, R., Spika, D., Wang, X.-S., Bannon, F., Ahn, J. V., Johnson, C. J., Bonaventure, A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62038-9 · Cited by 2,614
Bhattacharjee, A., Richards, W. G., Staunton, J. E., Li, C., Monti, S., Vasa, P. P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,558
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,056
Cited by
Sorted by citations
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 390
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182
Self-citationKRAS G12C inhibition produces a driver-limited state revealing collateral dependencies
Lou, K., Steri, V., Ge, A. Y., Hwang, Y. C., Yogodzinski, C. H., Shkedi, A. R., Choi, A. L. M., Mitchell, D. C., Swaney, D. L., Hann, B., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aaw9450 · Cited by 175
Dost, A. F. M., Moye, A. L., Vedaie, M., Tran, L. M., Fung, E., Heinze, D. M., Villacorta-Martín, C., Huang, J., Hekman, R. M., Kwan, J., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.07.022 · Cited by 166
Metadata
- Authors
- Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., Le Quesne, J., Dick, C., Vousden, K. H., Martins, C. P., & Murphy, D. J.
- Affiliations
- University of Glasgow (GB)
- Cancer Research UK Scotland Institute (GB)
- MRC Cancer Unit (GB)
- MRC Toxicology Unit, Leicester LE1 7HB, UK.
- National Health Service (GB)
- Corresponding author
- Kruspig, Björn
- Monteverde, Tiziana
- Murphy, Daniel J.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-06-20
- Volume
- 10
- Issue
- 446
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6881183
- OpenAlex
- W2809593667
- Cited by
- 111
- References
- 47
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 19 · 2020: 16 · 2019: 15 · 2018: 6
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science Translational Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Funders
- Medical Research Council (5TS30)
- British Lung Foundation (APHD13-5, CSOBLF RG16-2)
- European Commission (CIG 618448, 705190 “NuSiCC”)
- Deutsche Krebshilfe (109220)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS mutation, lung cancer, lung carcinogenesis, Ras signaling, MEK inhibition, combination therapy, tumor progression, cell proliferation
- MeSH terms
- Adenocarcinoma of Lung, Animals, Humans, Lung Neoplasms, Mutation, Phosphorylation, Signal Transduction, Gene Expression Regulation, Neoplastic, Survival Analysis, Proto-Oncogene Proteins p21(ras), Apoptosis, Disease Progression, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, Gene Regulatory Networks, Carcinogenesis, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
